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WHO/EORTC classification of cutaneous
lymphomas 2005: histological and
molecular aspects
Abstract: The new WHO/EORTC classification for cutaneous
lymphomas comprises mature T-cell and natural killer (NK)-cell
neoplasms, mature B-cell neoplasms, and immature hematopoietic
malignancies. It reflects the unique features of lymphoproliferative
diseases of the skin, and at the same time it is as compatible as possible
with the concepts underlying the WHO classification for nodal
lymphomas and the EORTC classification of cutaneous lymphomas.
This article reviews the histological, phenotypical, and molecular
genetic features of the various nosological entities included in this new
classification. These findings always have to be interpreted in the
context of the clinical features and biologic behavior.
Aim: To review the histological, phenotypical and molecular genetic
features of the various nosological entities of the new WHO/EORTC
classification for cutaneous lymphomas.
Methods: Extensive review of the literature cited in Medline and own
data of the authors.
Results: The WHO/EORTC classification of cutaneous lymphomas
comprises mature T-cell and NK-cell neoplasms, mature B-cell
neoplasms and immature hematopoietic malignancies. It reflects the
unique features of primary cutaneous lymphoproliferative diseases.
Conclusion: This classification is as much as possible compatible with
the concept of the WHO classification for nodal lymphomas and the
EORTC classification of cutaneous lymphomas. The histological,
phenotypical and molecular genetic features always have to be
interpreted in the context of the clinical features and biologic behavior.
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Over the past 50 years, the classification of lymphomas
has been a source of controversy, both for those study-
ing primarily nodal disease and those interested in
cutaneous lymphomas, as well as an area of interdisci-
plinary disagreement. There never will be a classifica-
tion for lymphomas that can cover the broad spectrum
of nodal and extranodal lymphomas at the same time
and fully reflect the many organ-specific biological
peculiarities. Nevertheless, one basic terminology
should be used for both nodal and extranodal
lymphomas.
During two consensus meetings in Lyon, France in
September 2003 and in Zu¨rich, Switzerland in
January 2004 and in many additional discussions, a
group of pathologists and dermatologists elaborated
the WHO/EORTC classification for primary lym-
phoproliferative disorders (LPD) of the skin1–4 which
reflects the specific features of cutaneous lymphomas.
The WHO/EORTC classification has been devel-
oped on the base of the EORTC classification for
cutaneous lymphomas5 and the WHO classification
for nodal lymphomas6 and respects the framework of
the basic WHO classification for nodal lymphomas.7
The clinical aspects of the new classification
recently have been reviewed.2 This article focuses
on the histological and molecular findings in the
various disease entities with special reference to the
differences between nodal and cutaneous
lymphomas.
WHO/EORTC classification for cutaneous
lymphomas
The distinct histological, phenotypic, and molecular
biological features of the entities listed in the new
WHO/EORTC classification for cutaneous lym-
phomas (Table 1)1,2,4 are presented.
Cutaneous T-cell lymphomas
Mycosis fungoides (MF)
Mycosis fungoides (MF), the prototype of cutaneous
T-cell lymphomas (CTCL), accounts for approxi-
mately 44% CL.2 MF initially presents in the skin
and shows a characteristic stepwise clinical progres-
sion with potential extracutaneous involvement.
Synonyms in other classifications
WHO/EORTC classification (2005): mycosis
fungoides
WHO classification (2001): mycosis fungoides
REAL classification (1997): mycosis fungoides
EORTC classification (1997): mycosis fungoides
Clinical features
The disease starts with patches, which after years or
even decades develop into thin and thick plaques. In
a minority of patients, the disease results eventually in
tumors and in dissemination to lymph nodes, blood,
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bone marrow, and internal organs. Involvement of
mucous membranes is an exception. The disease does
not develop continuously, but instead shows a step-
wise progression, suggesting that the steps reflect
cumulative mutations in various genes involved in
the pathogenesis of the neoplastic process.8,9
Histology
The histologic diagnosis of early MF usually is difficult
to establish, as the disease may closely resemble der-
matitis in its early stages.10 The most specific finding,
seen in only 10% of lesions, are Pautrier micro-
abscesses (Fig. 1A). The presence of medium-to-large
hyper-convoluted cerebriform cells in the epidermis
larger than dermal lymphocytes, showing a clear peri-
nuclear halo (haloed lymphocytes), or lymphocytes in
clusters in the dermis, and lymphocytes aligned within
the basal layer are typical but not specific features.11
In early MF, presence of lymphocytes with strikingly
irregular nuclear contour and/or variable nuclear and
cytoplasmic features is of diagnostic value with a sen-
sitivity of 53.3% and a specificity of 88.9%12. There
usually is little spongiosis. A study analyzing 745
biopsy specimens of early MF13 demonstrated that
epidermotropism of lymphocytes was almost always
present, but missing in 4% of cases. The combination
of a patchy band-like infiltrate and elongated,
Table 1. The WHO/EORTC classification for cutaneous lymphomas1–3
Mature T-cell and NK-cell neoplasms
Mycosis fungoides (MF)
Variants of MF
Pagetoid reticulosis (localized disease)
Folliculotropic, syringotropic, granulomatous variants
Subtype of MF
Granulomatous slack skin
Se´zary syndrome
CD30þ T-cell lymphoproliferative disorders of the skin
Lymphomatoid papulosis
Primary cutaneous anaplastic large cell lymphoma
Subcutaneous panniculitis-like T-cell lymphoma*
Primary cutaneous peripheral T-Cell lymphoma (PTL), unspecified
Subtypes of PTL
Primary cutaneous aggressive epidermotropic CD8þ T-cell lymphoma (provisional)
Cutaneous gamma/delta-positive T-cell lymphoma (provisional)
Primary cutaneous CD4þ small/medium-sized pleomorphic T-cell lymphoma (provisional)
Extranodal NK/T-cell lymphoma, nasal type†
Hydroa vacciniforme-like lymphoma (variant)
Adult T-cell leukemia/lymphoma†
Angioimmunoblastic T-cell lymphoma†
Mature B-cell neoplasms
Cutaneous marginal zone B-cell lymphoma (MALT-type)
Primary cutaneous follicle center lymphoma
Growth patterns
Follicular
Follicular and diffuse
Diffuse
Cutaneous diffuse large B-cell lymphoma, leg type
Cutaneous diffuse large B-cell lymphoma, others
Intravascular large B-cell lymphoma†
Lymphomatoid granulomatosis†
Chronic lymphocytic leukemia†
Mantle cell lymphoma†
Burkitt lymphoma†
Immature hematopoietic malignancies
Blastic NK-cell lymphoma‡ CD4þ/CD56þ hematodermic neoplasm
Precursor lymphoblastic leukemia/lymphoma†
T-lymphoblastic lymphoma†
B-lymphoblastic lymphoma†
Myeloid and monocytic leukemias†
Hodgkin lymphoma
*Definition is restricted to lymphomas of alpha/beta T-cell origin.
†This table also contains entities of extracutaneous lymphomas frequently involving the skin as a secondary site.
‡Recent evidence suggests an origin from a dendritic cell precursor. In recognition of uncertain histogenesis the term CD4þ/CD56þ hematodermic
neoplasm is preferred.
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Fig. 1. A) Patch stage of mycosis fungoides (MF): epidermotropic lymphocytic infiltrate forming Pautrier microabscesses; intraepidermal atypia of
the intraepidermal lymphocytes. B) Early stage of MF: superficial perivascular lymphocytic infiltrate with epidermotropism along the basal layer
(lining up) and in upper levels of the epidermis. C) Plaque stage of MF: dense band-like lymphoid infiltrate with epidermotropism. Inset: dense
infiltrate of atypical lymphocytes. D) MF in transformation: dense lymphocytic infiltrate reaching deep into the subcutaneous fat and ulceration.
E) Plaque stage of MF: predominance of CD4 (top) over CD8 cells (bottom). F) CD8þ MF: The cells are CD4– (top) and CD8þ (bottom).
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rounded rete ridges, known as a psoriasiform liche-
noid pattern is particularly common. A pattern resem-
bling interface dermatitis is present in more than half
of the biopsies.13 Early patches of MF usually lack
eosinophils or plasma cells.
The final diagnosis is based on a combination of
specific histologic parameters without the necessity
of confirmatory immunophenotyping in the vast
majority of cases.10,11 Both interobserver and
intraobserver variability is generally high.14
In the thin plaque stage, the histological findings
are more often fully diagnostic (Fig. 1B). There is a
dense infiltrate with lymphocytes lining up in the
basal layer, especially at the tips of the rete ridges
with epidermotropism of single cells. The majority
of cells are small, differentiated lymphocytes with
round or only slightly cerebriform nuclei. Haloed
cells may predominate in the epidermis. There may
be mild acanthosis, hyperkeratosis, edema or fibrosis
of the papillary dermis. There is proliferation of
postcapillary venules with prominent endothelial
cells, simulating histiocytic giant cells. The infiltrate
may contain an admixture of eosinophils, plasma
cells, macrophages, and dermal dendritic cells.15,16
The thick plaque stage (Fig. 1C) is typified by a
dense, subepidermal, usually band-like infiltrate
containing a high number of cells with cerebriform
nuclei. Epidermotropism is more prominent with
small intraepidermal clusters (two to three cells) of
lymphocytes. Typical Pautrier microabscesses are
seen only in approximately 10% of cases.
Subcorneal bullous formation may result from con-
fluence of Pautrier microabscesses.17
With progression from plaque stage to tumor
stage (Fig. 1D), the dermal infiltrates become more
diffuse, and epidermotropism may disappear. The
proportions of tumor cells increase both in number
and size, and may include cells with small, medium-
sized and large cerebriform nuclei, and blast cells
with prominent nuclei and intermediate forms.
There is a concomitant decrease in the numbers of
reactive T cells and dendritic cells. Eosinophils and
plasma cells usually are present.
Immunophenotype
The immunophenotypical prototype of MF is a
CD2þ, CD3þ, CD4þ, CD5þ, CD45ROþ, CD8–,
TCRbetaþ, and CD30– phenotype (Fig. 1E)
CD4– –. A CD8þ phenotype has been described
(Fig. 1F), which otherwise seems to be similar to
MF. During progression of the disease loss of CD7,
CD2 and CD5 may be seen especially in the epider-
motropic cerebriform cells. When large blast stage
occur in tumors (large-cell transformation), CD4þ
epidermotropic cells can express a cytotoxic
phenotype (TIA-1 and granzyme B) and CD30.
Rare cases of CD56þ MF have also been observed.18
Molecular findings and genetics
Monoclonal rearrangement of T-cell receptor
gamma genes is a common finding in plaque and
tumor stage of MF but is found in only half of the
cases of early MF.
There are only very few data on chromosome
aberrations in primary CTCL. Molecular cytoge-
netic analysis of CTCL using comparative genomic
hybridization (CGH) analysis has identified com-
mon genetic alterations in SS and MF.19 The most
frequent losses involve chromosomes 1p, 17p, 10q/
10 and 19. Commonly detected chromosomal gains
involve 4/4q, 18 and 17q/17. A similar pattern of
chromosomal instability is seen in both MF and
SS.19 Numerical aberrations of chromosomes 6,
13, 15, and 17, marker chromosomes, and structural
aberrations of chromosomes 3, 9, and 13 were
increased in MF compared with healthy controls.20
Detailed molecular expression analysis of cuta-
neous T-cell lymphoma is not available. Some onco-
genic alterations have been demonstrated, such as
functional inactivation of the Fas receptor21 consti-
tutive activity of STAT3,22 or the inactivation of the
p16INK4a gene via deletion or promoter
hypermethylation.23,24
On the other hand, inactivation of several tumor
suppressor genes in CTCL, such as SHP-1,25 p15,
p16,26 and hMLH127 has been reported. Protein
expression and phosphorylation assays revealed
that lack of SHP-1 expression, an important nega-
tive regulator involved in signaling through recep-
tors for cytokine/growth factors such as c-kit ligand,
interleukin (IL)-3, IL-2, IL-4, and IL-13 and others,
is frequent in malignant T cells and results from
methylation of the SHP-1 gene promoter. The per-
sistence of signals generated by IL-2R and possibly
other receptor complexes may be important in the
pathogenesis of T-cell lymphomas.25 Whittaker and
colleagues showed aberrant p15 protein expression
in 85% of patients analyzed with p15 gene abnorm-
alities and abnormal p16 expression in 59% with
p16 gene abnormalities. These abnormalities were
not dependent on cutaneous stage of disease, leading
to the suggestion that abnormalities of the p15 and
p16 genes may be common in both early and
advanced stages of MF and SS and that these
genes may be inactivated by allelic loss and aberrant
promoter methylation.26 Microsatellite instability
(MSI) was found to be more prevalent in tumor
stage MF than early-stage disease and was asso-
ciated with an older age of onset of MF.27 In more
than half of the patients with MSI, abnormal
hMLH1 protein expression could be detected, and
WHO/EORTC classification of cutaneous lymphomas
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it has been argued that the development of a
mutator phenotype may contribute to disease pro-
gression in MF. Recently, a genome-wide scale dif-
ferential methylation hybridization analysis,
comparing aggressive CTCL entities such as trans-
formed MF and CD30– large T-cell lymphoma with
indolent entities (CD30þ large T-cell lymphoma)
revealed a relative hypermethylated state of putative
tumor suppressor genes such asbcl7a, PTPRG, and
thrombospondin.28 The hypermethylated state of sev-
eral tumor suppressor genes involved in DNA repair,
cell cycle, or apoptosis, lead to inactivation of these
genes, thus promoting leukemogenesis of CTCL.
Whether these events are causative or an epipheno-
menon remains to be elucidated. Tumor suppressor
gene hypermethylation may render these tumors
amenable to therapeutic interventions with demethy-
lation agents.
A study employing microsatellite analysis of
microdissected tumor tissue suggested that CTCL
may evolve by multilineage progression and that
tumor subclones in MF can be detected in early
disease stages.29
Variants and subtypes
Apart from the classical form of MF, there are
several variants and subtypes of this disease includ-
ing folliculotropic MF, pagetoid reticulosis and
granulomatous slack skin. Apart from those listed
in the WHO/EORTC classification, there are bul-
lous, granulomatous, hypo- or hyperpigmented,
hyperkeratotic and other forms of MF.30,31
Folliculotropic MF (pilotropic MF, folliculocentric
MF) with or without follicular mucinosis shows a
predilection for hair follicles. Clinically, the disease
manifests itself as erythematous patches or plaques
with follicular hyperkeratosis producing comedo-like
plugs and often hair loss. The face and upper trunk
are the sites of predilection. Pseudotumorous forms
dominated by follicular epithelial hyperplasia rather
than lymphocytic proliferation have been
reported.32
Histologically, there is a dense lymphocytic infil-
trate of small to medium-sized cells with irregular
nuclei, surrounding and infiltrating the hair follicles
and sparing interfollicular areas (Fig. 2). Often,
nuclear atypia of lymphocytes is not prominent.33
The follicles may show cystic dilatation, cornified
plugging and in some cases mucin deposition.
Since some patients experience an aggressive
clinical course with large-cell transformation and
lymph node involvement, folliculotropic MF
carries a worse prognosis than classic MF.34–36
Changes in intercellular adhesion receptors may
account for the phenomenon of folliculotropism in
follicular MF.
Pagetoid reticulosis (PR) is a low-grade malignant
variant of MF with characteristic histologic features,
but various phenotypes. Originally two forms of PR
were described, namely disseminated by Ketron and
Goodman37 and unilesional PR in 1931 by
Woringer and Kolopp.38 The term ‘pagetoid reticu-
losis’ was proposed by Braun-Falco and colleagues
because of the clinical and the histological appear-
ance.39 Clinically, the differential diagnosis of the
unilesional form includes solitary lesions of psoriasis,
Bowen disease, extramammary Paget disease, or
circumscribed forms of chronic dermatitis.
Histologically, the acanthotic epidermis shows
sponge-like disaggregation by medium-to-large-
sized atypical lymphoid cells with vacuolated, abun-
dant cytoplasm, singly or arranged in clusters40
(Fig. 3A,B). Superficial spreading type of malignant
melanoma and Paget disease may mimic PR but can
readily be distinguished by cytomorphologic and
immunophenotypic features (S-100; CEA;
EMA).41,42 Most cases of PR express a T-helper
phenotype: CD3þ, CD4þ, CD5þ and CD8–.43
There are reports on CD8þ cases44,45 or PR expres-
sing a gamma/delta phenotype46 which should be
classified among the gamma/delta T-CL. The pro-
nounced epidermotropism of neoplastic cells in PR
may be due to their strong expression of receptors
(CLA and alpha E beta 7), seen also in non-neoplas-
tic conditions, interacting with endothelial cells and
keratinocytes, respectively.47
Fig. 2. Follicular mycosis fungoides (MF): deep dense lymphocytic
infiltrate with folliculotropism but low epidermotropism. Follicular
epithelium shows mucinous degeneration forming mucin lakes.
Inset: detailed view of atypical lymphocytes infiltrating the follicular
epithelium.
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Granulomatous slack skin (GSS)
Granulomatous slack skin (GSS) is a rare form of
CTCL, nosologically related to MF and is therefore
referred to as subtype of MF in the WHO/EORTC
classification, clinically characterized by the
development of bulky skin lesions in the major skin
folds. The differentiation between variant and
subtype of an entity is somehow arbitrary but is
helpful in pointing to minor (variants) and major
(subtype) differences from the prototype CTCL
(MF). This nomenclature is also used for extracuta-
neous tumors of the hematopoietic and lymphoid
tissues.6
Synonyms in other classifications
WHO/EORTC classification (2005): subtype of
mycosis fungoides
WHO classification (2001): not listed
REAL classification (1997): not listed
EORTC classification (1997): granulomatous slack
skin
Histology
Early lesions of GSS display a band-like infiltrate
of small lymphocytes without significant nuclear
atypia.48 More advanced lesions show a dense lym-
phocytic infiltrate throughout the entire dermis, but
unlike tumors of MF, the lymphocytes are usually
small. The diagnostic hallmark is numerous multi-
nucleated histiocytic giant cells, which are scattered
throughout the background of the dense lymphocy-
tic infiltrate. These giant cells contain 20–30 nuclei
mostly located at the periphery of the cytoplasm
(Fig. 4), Elastophagocytosis and emperipolesis, i.e.
phagocytosis of lymphoid cells by multinucleated
giant cells, are present. Elastic stains demonstrate
the loss of elastic fibers at the sites of the infiltrates
in all dermal layers. Ultrastructurally, the lympho-
cytes show hyperchromatic cerebriform nuclei simi-
lar to those seen in MF and SS.49
Immunophenotype
The lymphoid tumor cells display a T-helper phe-
notype with the expression of CD4, CD45RO.
There may be loss of other T-cell markers such as
CD3, CD5, or CD7. In rare cases, the tumor cells
express CD30.50 The giant cells are of histiocytic
origin and thus are positive for histiocytic markers
such as CD68 and Mac387.
Fig. 4. Granulomatous slack skin: dense superficial and deep lym-
phocytic infiltrate with numerous scattered large, histiocytic multi-
nucleated giant cells (detail in the inset).
A
B
Fig. 3. A) Pagetoid reticulosis: mostly superficial lymphocytic infil-
trate showing prominent epidermotropism with spongiform disag-
gregation of the epidermis. B) Pagetoid reticulosis: prominent
epidermotropism of lymphocytes with nuclear atypia and clear
cytoplasm (halo cells).
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Molecular findings and genetics
Clonal rearrangement of TCR genes can be found
in most cases and is a useful diagnostic tool in early
stages of the disease.51 Trisomy 8 has been reported
in two cases.52–54
No molecular expression analysis has been
reported, probably because of the rarity of the disease.
Se´zary syndrome (SS)
This leukemic form of CTCL is defined by erythro-
derma, lymphadenopathy, and presence of neoplas-
tic T-cells (Se´zary cells) in skin, lymph nodes, and
peripheral blood with an absolute Se´zary cell count
of at least 1000 cells/mm3. Clinically edema, hyper-
keratosis of palms and soles, and therapy-resistant
pruritus are typically present. Recently, the follow-
ing criteria for the diagnosis of SS were recom-
mended by the International Society for
Cutaneous Lymphoma (ISCL): an absolute Se´zary
cell count of at least 1000 cells/mm3; demonstration
of immunophenotypical abnormalities (expanded
CD4þ T-cell population resulting in a CD4/CD8
ratio more than 10 and loss of any or all of the T-
cell antigens CD2, CD3, CD4, and CD5, or both);
or the demonstration of a T-cell clone in the per-
ipheral blood by molecular or cytogenetic studies.55
Synonyms in other classifications
WHO/EORTC classification (2005): Se´zary
syndrome
WHO classification (2001): Se´zary syndrome
REAL classification (1997): Se´zary syndrome
EORTC classification (1997): Se´zary syndrome
Histology
The histological spectrum of SS is similar to that of
MF although there are minor differences.56,57
Although Pautrier microabscesses and acanthosis
are more frequently present in SS than in MF,
however, recent studies suggest that histological fea-
tures do not reliably allow differentiation between
the two disorders.56,58
The most prevalent finding in skin biopsies from
SS patients is a subepidermal perivascular or band-
like monotonous infiltrate composed of predomi-
nantly small lymphocytes with or without nuclear
atypia (Fig. 5A).15,59 A few eosinophils and plasma
cells may be admixed. The epidermis often shows
psoriasiform acanthosis. Epidermotropism and lin-
ing up of lymphocytes with cerebriform nuclei (MF-
like pattern) is found in approximately 20–40%, half
of which exhibit Pautrier microabscesses59,60 which
are a specific, but not a regular finding in epidermo-
tropic CTCL such as MF and SS57 (Fig. 5B). Edema
is often present in initial stages of epidermotropic
CTCL but may be replaced over time by fibrosis of
papillary dermis. Occasionally, granulomatous fea-
tures can be seen in SS lesions.59,61 Both intraobser-
ver and interobserver variability is high in the
diagnosis of SS.62 Non-specific findings are present
in one-third of the biopsies.60
Immunophenotype
Se´zary cells are mature helper T cells with a mem-
ory cell phenotype, showing the following immuno-
profile: CD2, CD3, CD4, CD5, CD45 RO, and
CD30–.63 The majority of SS cells are also
CLAþ64 and CD7–.65 However, further studies
have shown that the neoplastic cell population is
present in both the CD7þ and CD7– subset in the
same patient.63 More recently, Bernengo et al.66
have demonstrated that CD4þ SS cells typically
loose CD26 and that a diagnosis of SS or MF with
hematological involvement can be made if the
CD26 subset exceeds 30% of the CD4þ cells.65 In
about two-third of patients with SS, complete loss of
T-cell antigens such as CD2, CD3, CD4, or CD5
may be found.66
Molecular findings and genetics
Using multiplex-fluorescence in situ hybridization
(M-FISH) and CGH, recurrent unbalanced translo-
cations associated with deletions can be detected in
samples from SS patients. Characteristic cytogenetic
A
B
Fig. 5. A) Se´zary syndrome: slight acanthosis and superficial, peri-
vascular lymphocytic infiltrate with epidermotropism. B) Se´zary
syndrome: detail epidermotropism of lymphocytes with formation
of Pautrier’s microabscesses.
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abnormalities in SS particularly involve 1p, 10q,
14q, and 15q.67 The dominant chromosome
changes in SS appear to be numerical losses rather
than structural aberrations, and as of yet, no reci-
procal balanced translocations with a leukemogenic
candidate fusion gene such as RA-PML in promye-
locytic leukemia have been detected. Chromosome
losses have been associated with clonal evolution
during disease progression through non-disjunction
of chromosomes. The underlying causative chromo-
somal instability in SS cells remains yet to be eluci-
dated in cell-cycle checkpoint studies.
An alternative approach to clarify important
molecular events in cutaneous lymphoma has been
taken on by SEREX-based identification of a
tumor-specific antigen.68 A heterogeneous expres-
sion pattern of cancer/testis antigens has been
demonstrated in SS, including Gage, MAGE-1,
MAGE-3, MAGE-C1, NY-ESO-1, and TS85.69
Recently, two differentiation antigens p140 and
SCS have been reported in circulating SS cells,
and p140 was also found in skin-infiltrating cells of
patients with SS.70 No differences in expression of
cellular interaction molecules, such as ICAM-1,
LFA-1, CD40, and CD40 ligand, exist between
MF and SS.58
The signal transducers and activators of transcrip-
tion (STAT) family members play an important role
in regulating T-cell activation.71 Dysregulated
expression of STAT5t, a naturally occurring
COOH-terminal truncated isoform of STAT5, in
malignant T cells in SS syndrome can suppress
STAT5-dependent gene expression, which may, in
turn, contribute to the cellular transformation.72
More recently, oligonucleotide array analysis has
allowed gene expression comparison between SS
cells and CD4þ T cells isolated from the blood of
patients with erythroderma secondary to atopic or
chronic dermatitis and of healthy volunteers. For the
analysis, the authors included SS patients with a
high percentage of CD4þ SS cells in the peripheral
blood mononuclear cells. The SS samples displayed
a relatively homogeneous gene-expression pattern
and could be distinguished from benign CD4þ T
cells using an unsupervised hierarchical clustering
analysis algorithm. Two genes (Twist and Ephrin
A4) were consistently upregulated, whereas tran-
scripts were nearly undetectable in any of the con-
trol samples in microarray experiments and
consecutive real-time quantitative PCR. The Twist
gene encodes a basic helix-loop-helix family tran-
scription factor involved in mesodermal differentia-
tion and is normally not expressed in lymphoid
cells.73,74 An oncogenic property of Twist has been
proposed via prevention of c-myc-induced apoptosis
by antagonizing the p53 pathway.75 Ephrin A4
(EphA4) belongs to the Eph receptor subfamily of
transmembrane protein–tyrosine kinases that are
preferentially expressed in neurons but has also
been detected in human T cells. Its involvement in
tumorigenesis is attractive, as it has been shown that
EphA4 can activate the JAK/STAT pathway.76,77
EphA4 expression in CTCL has not been reported
at the protein level. If indeed activation of EphA4
can be pinpointed as an early or crucial event in
transformation of T cells, it may be an attractive
target for antitumor therapy, analogous to the suc-
cess story of inhibition of BCR-ABL by imatinib in
chronic myelogenous leukemia patients.
Consistent with earlier reports, high expression of
JunB, versican, TRAIL, T-plastin, Kir3DL2, integ-
rin b1, as well as low expression of STAT4, TGF-b
receptor II, Fas, and CD26 have been found in SS
T cells. Contradictory to previous reports, increased
rather than decreased levels of TIA-1 and SHP-1
tumor suppressor transcripts were recently
described.78 Kari and colleagues79 performed filter
array analysis on partly purified SS cells, and
compared their expression pattern to in vitro Th1-
and Th2-skewed PBMCs. The array data were
validated by real-time qPCR. One of the main
objectives was to develop biomarkers for identifica-
tion of clinically difficult-to-detect patients with low
tumor burden. This study suggested that the loss of
expression of Th1-skewing STAT4, together with
increased expression of RhoB and other genes, can
be used in penalized discriminant analysis (PDA80)
to separate patients with SS cell counts as low as 5%
from control patients with inflammatory diseases or
from Th2-skewed blood samples. In addition,
short-term survivors of SS syndrome, independent
of their tumor burden, have a detectably different
gene expression pattern from patients classified as
long-term survivors. One explanation could be
that the malignant cells impose, via their direct or
indirect cytokine release, an expression pattern on
other PBMCs that may be detected as a CTCL
signature.
The two published gene-expression analysis
studies on SS cells address different questions, rely
on different sampling of patient material, and use
different data analysis methods, perhaps explaining
the study discrepancies. For a more accurate study
of expression analysis of tumor cells in SS syndrome,
a thorough clone purification by fluorescence-
activated cell sorting of the Vb TCR domain may
prove to be advantageous.
CD30þ T-cell lymphoproliferative disorders of the skin
CD30þ T-cell LPD of the skin (CD30þ LPD)
comprise a clinical and morphologic spectrum of
diseases including lymphomatoid papulosis (LyP),
primary cutaneous anaplastic large-cell lymphoma
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(ALCL), as well as so-called borderline cases.81–83
The hallmark of the tumor cells is the expression of
CD30, a cytokine receptor belonging to the tumor
necrosis factor receptor (TNFR) superfamily.
Although they share CD30 expression as a common
immunophenotypic feature, the diseases within
the group of CD30þ LPD differ in their clinical
and histological presentations.84,85 The final diagno-
sis has to include careful correlation of histologic
findings with clinical manifestations of the disease
when evaluating infiltrates with CD30þ tumor
cells.86
Lymphomatoid papulosis
Lymphomatoid papulosis (LyP), described in 1968
by Macaulay, is a chronic recurrent, self-healing
papulo-nodular skin eruption with histologic fea-
tures of a malignant lymphoma.87
Synonyms in other classifications
WHO/EORTC classification (2005): CD30 lym-
phoproliferative disorders of the skin – lymphoma-
toid papulosis
WHO classification (2001): CD30 lymphoprolifera-
tive disorders of the skin – lymphomatoid papulosis
REAL classification (1997): not listed
EORTC classification (1997): lymphomatoid
papulosis
Histology
The histological features of LyP are variable and
depend on the stage of the lesions and disease.
Three histologic patterns have been differentiated
(Table 2).88,89 In type A (Fig. 6A), tumor cells are
large atypical cells, resembling Reed-Sternberg-like
cells (Fig. 6B). In type B, a band-like infiltrate of
small cerebriform cells is found. The type C lesions
exhibit large atypical lymphoid cells growing in
cohesive sheets with only a few intermingled reactive
inflammatory cells (Fig. 6C). Epidermotropism can
be present. In addition, in type A lesions, there are
numerous inflammatory cells such as neutrophils,
eosinophils, and histiocytes as well as few plasma
cells and a prominent edema in the upper dermis.
Variants of lymphomatoid papulosis include cases
with a perifollicular distribution and those with lym-
phocytic vasculitis or dermal mucin deposits.88
There may be various histologic types in individual
patients at the same time, depending also on the
stage and age of the lesion.90
Differentiation between LyP and other CD30þ
LPD must be based on correlation of clinical pre-
sentation and histologic findings.
Immunophenotype
The tumor cells in LyP express the marker profile of
mature T cells [CD3þ, CD4þ, CD8–, CD30þ, and
CD56þ (10%)] (Fig. 6D) and of activated T cells
[HLA-DR and CD25 (interleukin 2-receptor)],
thus representing a proliferation of activated T-
helper cells.91–95 Usually one or more T-cell anti-
gens such as CD2 and CD5 are expressed, whereas
CD7 expression is often absent. CD15, which is a
characteristic marker for Reed-Sternberg cells in
Hodgkin lymphoma, is not expressed by tumor
cells in LyP. In contrast to tumor cells expressing
CD30 as a hallmark of LyP type A and type C, the
small tumor cells with cerebriform nuclei in LyP
type B are usually negative for CD30. Recent stu-
dies indicate that almost all tumor cells in LyP and
ALCL express cytotoxic molecules such as TIA-1
and granzyme B.96 The presence of large CD30þ T
cells is not diagnostic per se for LyP, as there is an
enlarging number of benign reactive conditions in
which CD30þ cells can be found.97
Molecular findings and genetics
The findings of translocation studies for t(2;5) are
controversial, showing translocation and the t(2;5)-
associated p80 NPM/ALK fusion protein in some
CD30þ cutaneous lymphoma and LyP98,99 whereas
it is absent in most cases.100 Furthermore, conflict-
ing data on the detection of clonality among the
large CD30þ tumor cells and small lymphocytes
have been reported.101,102 On the other hand, in
cases in which LyP is associated with MF, both
diseases have been shown to harbor the same T-
cell clone, indicating that both diseases are different
clinical manifestations of the same T-cell
proliferation.103
Primary cutaneous anaplastic large-cell lymphoma
Primary cutaneous and primary nodal CD30þ
ALCL are distinct clinical entities which share his-
tologic features and display a certain overlap in
immunophenotype, but differ in age of onset,
Table 2. Histologic types of lymphomatoid papulosis (Lyp)89
Histologic type Morphologic criteria
LyP type A Scattered CD30þ blast cells in an extensive inflammatory infiltrate
LyP type B Mycosis fungoides-like features with atypical small CD30– T cells with cerebriform nuclei and epidermotropism
LyP type C Large clusters of CD30þ cells with few inflammatory cells, histologically suggesting ALCL
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genetic features, etiology, and prognosis.104–106
Clinically, cutaneous ALCL presents as a single or
multiple grouped nodules or tumors, confined to
one extremity or body area.
Synonyms in other classifications
WHO/EORTC classification (2005): primary cuta-
neous anaplastic large-cell lymphoma
WHO classification (2001): primary cutaneous ana-
plastic large-cell lymphoma
REAL classification (1997): anaplastic large-cell
lymphoma, CD30þ
EORTC classification (1997): primary cutaneous
large-cell T-cell lymphoma, CD30þ
Histology
There is a dense nodular infiltrate of atypical lym-
phoid cells with pleomorphic, anaplastic, or immu-
noblastic cytomorphology, extending through all
levels of the dermis into the subcutis (Fig. 7A).
Epidermotropism is an inconsistent feature. The
morphologic hallmark are large, bizarre cells with
irregularly shaped nuclei and one or multiple
nucleoli. They may be multinucleated, and often
have abundant, pale, or eosinophilic cytoplasm
(Fig. 7B). Tumor cells usually grow in dense cohe-
sive sheets, reminiscent of nodular malignant mela-
noma or undifferentiated carcinoma. Mitoses are
frequent. Clusters of small reactive lymphocytes
are found within and around the tumor.
Eosinophils, plasma cells, and accessory dendritic
cells usually are not prominent in ALCL.
Neutrophil-rich or pyogenic CD30þ ALCL features
small aggregations or scattered CD30þ medium-to-
large pleomorphic lymphoid cells within an exten-
sive infiltrate of neutrophils.107,108 Recently, kera-
toacanthoma-like epidermal hyperplasia overlying
the lymphoid infiltrate was reported.109
Immunophenotype
ALCL is defined by CD30 expression of at least
75% of the large pleomorphic, anaplastic, or immu-
noblastic lymphoid cells (Fig. 7C). Primary cuta-
neous CD30þ ALCL have an activated T-cell
phenotype with expression of T-cell-associated anti-
gens CD2, CD3, CD4, and CD45RO and activa-
tion markers such as CD25 (IL-2R), CD30, CD71,
and HLA-DR. Variable loss of T-cell antigens
(CD2, CD3, and CD5) can be found.110
Expression of T-cell markers on tumor cells is
usually weaker than on reactive lymphocytes.110 In
contrast to nodal ALCL, primary cutaneous forms
do not express EMA but may express the cutaneous
lymphocyte antigen (CLA and HECA-452) and
homeobox gene HOXC5.111 Primary cutaneous
ALCL is negative for the anaplastic lymphoma-
related tyrosine kinase (ALK) in the vast majority
of cases.
A B
DC
Fig. 6. A) Lymphomatoid papulosis: dense
superficial and deep wedge-shaped infil-
trate, slight acanthosis, and parakeratosis
of the overlying epidermis. B)
Lymphomatoid papulosis: Medium-to-
large-sized pleomorphic or anaplastic
tumor cells. C) Lymphomatoid papulosis:
dense superficial and deep lymphocytic
infiltrate with central necrosis and ulcera-
tion. D) Lymphomatoid papulosis: tumor
cells show CD30 positivity.
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Molecular findings and genetics
Over 90% of cases of primary cutaneous ALCL
display clonal rearrangement of TCR genes by
Southern blot and PCR.112 A high percentage of
nodal CD30þ ALCLs have a t(2;5)(p23;q35) trans-
location resulting in expression of t(2;5)-associated
p80 NPM/ALK fusion protein. This translocation
is never or extremely rarely found in primary cuta-
neous CD30þ lymphomas. This is of particular
importance because lack of ALK expression in cuta-
neous lymphomas is not a prognostic factor,
whereas ALK– nodal lymphomas show a sig-
nificantly worse prognosis compared to their
ALKþ counterparts.113 Systemic ALCL may pre-
sent with cutaneous disease, and the identification
of ALK expression is helpful in this distinction. In
primary cutaneous ALK–-ALCL, disease progres-
sion is not dependent on p53 mutation or conver-
sion to ALK positivity.114
A recent study on gene expression pattern com-
paring ALKþ and ALK– tumor cells of primary
systemic ALCL showed significant discriminator
cDNAs allowing a correct grouping of all ALKþ
and ALK– tumors. However, a clear picture of the
dominant signal-transduction pathway activated by
NPM-ALK failed to emerge from this microarray
data.115
Subcutaneous panniculitis-like T-cell lymphoma
Subcutaneous panniculitis-like T-cell lymphoma
(SPTCL) is a lymphoproliferative disease originating
and presenting primarily in the subcutaneous fat
tissue, simulating panniculitis. Only SPTCLs
expressing an a/b phenotype are referred as
SPTCL sui generis in the WHO/EORTC classifica-
tion, whereas cases with a g/d phenotype are
included in the group of peripheral T-cell lympho-
mas, not otherwise specified (NOS).
Synonyms in other classifications
WHO/EORTC classification (2005): subcutaneous
panniculitis-like T-cell lymphoma
WHO classification (2001): subcutaneous panniculi-
tis-like T-cell lymphoma
REAL classification (1997): subcutaneous panniculi-
tis-like T-cell lymphoma
EORTC classification (1997): subcutaneous panni-
culitis-like T-cell lymphoma
Histology
The histopathologic hallmark of this type of CTCL
is the subcutaneous localization and growth pattern
of usually non-epidermotropic focal infiltrates,
which involve predominantly the lobules of the sub-
cutaneous fat and simulate lobular panniculitis
A
B
C
Fig. 7. A) Primary cutaneous ALCL: deep reaching circumscribed
infiltrate of pale lymphoid cells. B) Primary cutaneous ALCL: dense
infiltrate of large lymphoid cells with broad cytoplasm and pleo-
morphic or anaplastic nuclei with coarse chromatin. Mitotic activity
is high. C) Primary cutaneous ALCL: characteristic CD30 positivity.
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(Fig. 8).116,117 Karyorrhexis and fat necrosis are pro-
minent features. The neoplastic lymphocytes usually
have hyperchromatic nuclei. Their sizes range from
small cells with round nuclei and inconspicuous
nucleoli to larger transformed cells with hyperchro-
matic nuclei. Rimming of adipocytes by tumor
cells is a common, but not specific, finding for
SPTCL (Fig. 8). Many vacuolated and foamy
histiocytes are found especially in areas of infiltration
and destruction, and erythrophagocytosis can be pre-
sent. Since the lymphoproliferative process is focal,
broad and deep biopsies are required to establish the
diagnosis. Cutaneous gd T-cell lymphomas can have a
panniculitis-like component, but commonly show both
dermal and epidermal involvement in addition to
subcutaneous disease.118–121 Plasma cells and reactive
lymphoid follicles are generally absent, in contrast to
lupus profundus, and other forms of lobular
panniculitis.
In some cases of SPTCL, the infiltrates in initial
phases may appear deceptively reactive, and the
differential diagnosis may be difficult.122,123 As the
disease evolves, the dermis may become involved
by tumoral infiltrates.124 Biopsies may demonstrate
either a non-specific panniculitis or lipomem-
branous panniculitis with calcified lipomembranes.
Therefore when SPTL is suspected, continued
follow-up with repeated biopsies is important.125
Immunophenotype
Because the phenotype of tumor cells has been linked
to aggressiveness of the disease, immunophenotyping
has both therapeutic and prognostic implications.
Tumor cells are derived from ab T cells with a
cytotoxic profile. They express T-cell-associated anti-
gens CD2þ, CD3þ, CD5þ, CD4–, CD8þ, CD43þ,
and cytotoxic proteins such as TIA-1, granzyme B,
and perforin.117 A TCR a/b (bF1þ) phenotype is
found. Clonal rearrangement of TCR genes is present
in the majority of the cases. Rarely, CD30þ forms of
SPTCL have been described.126,127
Molecular findings and genetics
The neoplastic cells show rearrangement of T-cell
receptor genes. In a series of six patients from the
UK those derived from g/d T cells carried a poor
prognosis and were CD56þ, while a more indolent
group was derived from ab T cells.120 Takeshita and
colleagues128 showed in 22 Japanese patients that
the 11 cases with CD56– SPTCL cells had charac-
teristics of CD3E–, CD8–, TcRbF1–, TIA-1–, and
granzyme Bþ T cells and were negative for apopto-
sis-promoting proteins CD95 (Fas), Bax, CPP32
(caspase 3), and p53. On the other hand, the 11
CD56þ cases presented with tumor cells positive for
CD3E, TIA-1, granzyme B, CD95, CD95L (FasL),
Bax, and CPP32.
Some cases of SPTCL, particularly in Asians,
were reported to be associated with EBV.129 Most
cases of SPTCL in Western countries are
EBV–.117,118,122 EBV and CD56 positivity can result
in confusion with nasal type NK lymphoma, which
often involves the subcutis.
Primary cutaneous peripheral T-cell lymphoma, unspecified
(PTL, NOS)
This category of peripheral T-cell lymphomas encom-
passes per definition all T-cell neoplasms that do not
fit into any of the better defined subtypes of T-cell
lymphoma/leukemia. As such it constitutes a hetero-
geneous group of diseases, representing less than
10% of all CTCL.130 They are CD30– and show an
aggressive behavior in most, but not all cases.
The following disorders have been included as
provisional entities in the group of PTL:
1. Cutaneous gamma/delta T-cell lymphoma
2. Primary cutaneous aggressive epidermotropic
CD8þ cytotoxic T-cell lymphoma
3. Primary cutaneous CD4þ small/medium-
sized pleomorphic T-cell lymphoma
Cutaneous gamma/delta T-cell lymphoma
Cutaneous g/d T-cell lymphoma (CGDTCL) is a
clonal proliferation of mature, activated g/d T cells
expressing a cytotoxic phenotype. This group
includes cases of SPTCL with a g/d phenotype. In
the 2001 WHO classification, these were grouped
together with SPTCL of a/b origin.131 Whether
cutaneous and mucosal g/d TCL are all part of
the same disease spectrum is unclear.132–134
Fig. 8. Subcutaneous panniculitis-like T-cell lymphoma: Mostly
lobular lymphoid infiltrate resembling lobular panniculitis; inset
shows rimming of lymphocytes around adipocytes.
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Histology
Three major histologic patterns can be seen: epider-
motropic, dermal, and subcutaneous. Usually more
than one histologic pattern is present in the same
patient either in different specimens or within a
single biopsy. Epidermal infiltration may occur,
ranging from mild epidermotropism to marked
pagetoid reticulosis-like infiltrates.46,135,136
Subcutaneous nodules may be panniculitis-like or
more solid in appearance and may show rimming
of fat cells similar to SPTCL of a/b origin.137
Dermal and epidermal involvement often coexists
with subcutaneous disease, in contrast to SPTCL
of a/b origin, which is mainly or exclusively sub-
cutaneous in distribution.117,120,137 The neoplastic
cells are generally medium to large in size with
coarsely clumped chromatin and irregular nuclei.
Apoptosis and necrosis are common, often with
vascular invasion.137
Immunophenotype
The cells are CD3þ, CD2þ, CD43þ, CD45ROþ,
CD15–, CD30–, CD20–, CD25–, and CD7þ/– , but
usually negative for CD5.132 Most CGDTCLs lack
both CD4 and CD8 but some are CD8þ121 and
may express natural killer cell-associated antigens
such as CD56.137 The cells are positive for TCR
g/d in frozen sections but lack bF1, a formalin-
resistent epitope of the a/b T-cell receptor. As
most laboratories only perform immunohistochem-
ical studies on formalin-fixed paraffin embedded
tissues, a lack of staining for b-F1 in an infiltrate
that has a T-cell phenotype is the best way to infer
the diagnosis of CGDTCL at present. The neoplas-
tic cells are positive for TIA-1 and the cytotoxic
proteins granzyme B, granzyme M, and
perforin.118,137,138
Molecular findings and genetics
The cells show clonal rearrangement of the TCR
gamma gene. TCR beta may be rearranged or
deleted, but is not expressed. Cases with predomi-
nant subcutaneous involvement express Vdelta2,
but this has not been studied in other
CGDTCL.117,139 EBV is generally negative in pri-
mary CGDTCL.134,140
Primary cutaneous aggressive epidermotropic CD8þ cytotoxic
T-cell lymphoma
Clinically, this form of CD8þ cutaneous lymphoma
differs from the slowly progressive CD8þ form simi-
lar to classic MF. It presents with erosive plaques
rather than patches. It exhibits an unfavorable prog-
nosis with rapid course.
Histology
There is a pagetoid pattern with prominent epider-
motropism showing acanthosis, spongiosis, necrosis,
and erosion (Fig. 9).141 In some cases, angiocentric
and angiodestructive features have been
described.142
Immunophenotype
The tumor cells express CD3, CD8, CD7,
CD45RA, CD45RO and beta F1 as well as TIA-1.
The CD2–, CD7þ phenotype seems to be associated
with a more aggressive course.143 With disease pro-
gression, tumor cells may acquire CD7 or loose
CD2.
Primary cutaneous CD4þ small/medium-sized pleomorphic
T-cell lymphoma
This is a non-cytotoxic CTCL characterized by a
predominance of small to medium-sized CD4þ
pleomorphic T cells with clinical features not com-
patible with MF.
Histology
The diffuse or nodular lymphoid infiltrate is mono-
morphous, predominantly perivascular and periad-
nexal and shows a tendency to extend to the
subcutaneous tissue. It consists of small-to-medium-
sized pleomorphic lymphoid cells with irregular
hyperchromatic nuclei and a pale scanty cytoplasm
(Fig. 10).144 A small proportion (<30%) of large
pleomorphic cells may be present.130 Mitoses are
observed. Eosinophils and plasma cells and histio-
cytes may be admixed. Epidermotropism is absent
Fig. 9. Primary cutaneous aggressive epidermotropic CD8þ cyto-
toxic T-cell lymphoma: pronounced epidermotropism and apopto-
tic keratinocytes.
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in most cases, but granulomatous features are found
in a subset of cases.145
Immunophenotype
These lymphomas have a CD3þ, CD4þ, CD8–, and
CD30– T-helper phenotype sometimes with loss of
pan T-cell markers. Cytotoxic proteins are not
expressed. CD20þ B cells may be admixed.146
Molecular findings and genetics
Clonal rearrangement of TCR genes has been
detected in almost all cases and may be useful in
distinguishing SPTCL from reactive T-cell infiltrate
(T-cell pseudolymphoma)144 which may also present
with a solitary plaque or nodule. No consistent cyto-
genetic abnormalities have yet been identified.
Cutaneous B-cell lymphomas
Cutaneous marginal zone B-cell lymphoma (MZL)
Synonyms in other classifications
WHO&/EORTC classification (2005): cutaneous
marginal zone B-cell lymphoma
WHO classification (2001): extranodal marginal
zone lymphoma of MALT type
REAL classification (1997): extranodal marginal
zone B-cell lymphoma
EORTC classification (1997): primary cutaneous
marginal zone B-cell lymphoma
Histology
The nodular or diffuse infiltrate is composed of
small to medium-sized lymphocytes possessing
slightly irregular nuclei with moderately dispersed
chromatin and inconspicuous nucleoli and an abun-
dant, pale cytoplasm (marginal zone cells)147,148
(Fig. 11A). Some cells have a monocytoid appear-
ance (reniform nuclei) or show prominent plasma
cell differentiation149 (Fig. 11B). The characteristic
‘inverse pattern’ may be seen on scanning magnifi-
cation, typified by darker centers surrounded by
brighter zones of pale-staining cells. Reactive germ-
inal centers with distinct mantle zones are com-
monly found in early lesions but may become
colonized by tumor cells as the disease progresses.
The colonized follicles lack a distinct germinal cen-
ter/mantle zone demarcation and have a more vari-
able cellular composition, including marginal zone
cells, centrocytes, and centroblasts. The cellular
population in the interfollicular areas is represented
by small to medium-sized, centrocyte-like, or mono-
cytoid cells with slightly irregular nuclei, moderately
dispersed chromatin, inconspicuous nucleoli, and a
rim of pale cytoplasm.147,148,150 Occasionally, the
infiltrate is arranged around adnexal structures.
Small lymphocytes can also surround and infiltrate
eccrine coils, in a manner analogous to that found in
the lymphoepithelial lesions of MALT lymphoma of
the gastrointestinal tract151 in some cases resulting
in vertical columns of cells.152
Primary cutaneous marginal zone B-cell lym-
phoma includes cases previously designated as pri-
mary cutaneous immunocytoma153 with high
numbers of monotypic plasma cells and lymphoplas-
macytoid cells showing intranuclear (Dutcher
bodies) and intracytoplasmic PASþ globular inclu-
sions, representing immunoglobulin deposits.
Immunophenotype
The neoplastic cells have the following immunophe-
notype: CD19þ, CD20þ, CD22þ, CD79aþ, CD5–,
CD10–, CD23–, bcl-6–, bcl-2þ154,155 (Fig. 11C–E).
Monotypic expression of immunoglobulin light
chains is seen in the majority of cases. It is best
assessed in cases in which plasmacytoid cells are
present in confluent aggregates rather than just
occurring as single, scattered cells. CD21 staining
often reveals regular and irregular networks of
follicular dendritic cells (FDCs) corresponding to the
sites of colonized follicles. In some cases large,
expanded, diffuse FDC networks may be seen.
Germinal center cells in the colonized and reactive
follicles as well as in the expanded FDC networks
are usually bcl-6þ and bcl-2–. CD30þ blasts can often
be found. There is a variable number of reactive
CD3þ T cells admixed to the neoplastic B cells
(Fig. 11F).
Molecular findings and genetics
IgH genes are clonally rearranged in the majority
(>70%) of cases.156 The most common transloca-
tion in gastric MZL, the t(11;18) involving the
API2/MLT genes, has not been demonstrated
in primary cutaneous MZL,157,158 but the
Fig. 10. Small-medium CD4þ TCL: dermal nodular lymphoid
infiltrate without epidermotropism (left) containing small to
medium sized pleomorphic tumor cells (right).
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t(14;18)(q32;q21) translocation involving IGH and
MALT1 was reported in approximately one-third
of cases.158 Fas gene mutations are present in a
minority of cases, similar to MZL of other extrano-
dal sites. Abnormalities of bcl-10 are absent.159
Primary cutaneous follicle center lymphoma
Synonyms in other classifications
WHO/EORTC classification (2005): primary cuta-
neous follicle center lymphoma
WHO classification (2001): cutaneous follicle center
lymphoma
REAL classification (1997): follicle center lym-
phoma, follicular
EORTC classification (1997): primary cutaneous
follicle center cell lymphoma
Follicle center lymphoma (FCL) and MZL are the
most common types of primary cutaneous B-cell
lymphomas. In contrast to MZL, FCL shows a predi-
lection for the scalp, forehead, and trunk.160–162
Synonyms for follicular lymphoma include
reticulohistiocytoma of the back or Crosti
lymphoma.163 Three growth patterns can be differen-
tiated: follicular, follicular and diffuse, and diffuse.
The most important differential diagnoses include folli-
cular pseudolymphoma (or reactive lymphoid
hyperplasia), MZL, and diffuse large B-cell lymphoma.
In contrast to nodal FCL, primary cutaneous FCLs
have a favorable prognosis with 5-year-survival rates
over 90%. They share their biologic behavior with
other extranodal forms of FCL as shown recently by
Goodlad and coworkers.164
Histology
Primary cutaneous FCL is defined as a neoplasm
with differentiation of follicle center cells (centro-
cytes and centroblasts) displaying a follicular, folli-
cular and diffuse or a diffuse growth pattern.
Grading of primary cutaneous FCL as in its nodal
counterpart based on the proportion of centroblasts
(Grades 1–3) is not prognostically relevant.
FCL shows a nodular or diffuse infiltrate within
the dermis, often extending into the subcutaneous
tissue (Fig. 12A), and contains a mixture of
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Fig. 11. A) Primary cutaneous marginal
zone B-cell lymphoma (MZL): Superficial
and deep nodular infiltrate, showing paler
zone around darker central areas. Germinal
centers are invaded by tumor cells. No epi-
dermotropism (grenz zone). B) Primary cuta-
neous MZL: infiltrate of small lymphocytes
with slight nuclear atypia (monocytoid
aspect). C) Primary cutaneous MZL: low
magnification shows CD20þ infiltrate sur-
rounded by CD20– T-cell population. D)
Primary cutaneous MZL: strong positivity
of the tumor cells for bcl-2 and remnants of
germinal centers are negative. E) Primary
cutaneous MZL: bcl-6 shows inverse reaction
to bcl-2: remnant ot the germinal center is
positive, cells of marginal zone are negative.
F) Primary cutaneous MZL: the centers are
CD3–, surrounded by population with CD3þ
cells.
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centrocytes and centroblasts (Fig. 12B) with variable
growth patterns, and may be follicular, follicular and
diffuse, or diffuse. In most cases, there is a subepi-
dermal Grenz zone. In contrast to the polymor-
phous follicular composition in reactive infiltrates
(pseudolymphoma or lymphoid hyperplasia) charac-
terized by an admixture of centrocytes, centroblasts,
immunoblasts, and tingible body macrophages,165
neoplastic follicles in FCL show a relatively mono-
morphic cellular composition with a low number of
mitoses, no or only few tingible body macrophages
and lack of starry sky features.166
Immunophenotype
The cells express B-cell markers and are CD19þ,
CD20þ, CD22þ, CD79aþ, CD5–, CD23þ/–, and
CD43 (Fig. 12C).165 CD10 is variably expressed
(often positive in follicular cases and more fre-
quently negative in lesions with diffuse pattern of
growth). Interfollicular CD10þ blasts may be pre-
sent singly or in clusters in follicular cases. Tumor
cells express bcl-6 and in most cases are negative
for bcl-2 (Fig. 12D).167 The MUM/IRF4 antigen,
which is positive in diffuse large B-cell lymphoma,
is not expressed in FCL. Monotypic staining for
surface immunoglobulins (sIg) is more often seen
in cryostat sections. Absence of detectable sIg
staining is common in tumors showing a diffuse
population of large follicular center cells. A major
difference between primary and secondary follicu-
lar lymphoma involving cutaneous sites is the
presence of the bcl-2 translocation, which is
usually present in 75–95% of nodal follicular
lymphomas. It is less often found in primary
cutaneous FCL.167 This discrepancy has led to
speculation that primary cutaneous FCL may be
a separate disease. The follicles are associated
with FDCs and are positive for CD21, CD23,
and CD35. Residual, scattered FDC may be
sometimes found in diffuse large-cell infiltrates.
Neoplastic cells are constantly CD5– and CD43–.
Admixed T cells may be abundant and sometimes
dominant, particularly in small, early lesions.
Molecular findings and genetics
Clonally rearranged immunoglobulin genes can be
regularly detected. Bcl-2 gene rearrangement and
t(14;18) chromosomal translocation are absent in
most cases.167–170 In systemic B-cell lymphoma,
inactivation of p15(INK4b) and p16(INK4a) is fre-
quently observed and may be associated with a
poor prognosis. In primary cutaneous B-cell lym-
phoma, p15(INK4b) and p16(INK4a) biallelic gene
abnormalities are common, most frequently as a
result of promoter hypermethylation.171 In a min-
ority of primary cutaneous FCL, chromosomal
imbalances have been identified by CGH analysis,
but a consistent pattern has not been
emerged.173,173 Storz and colleagues174 were the
first to analyze expression profiles of primary cuta-
neous B-cell lymphoma; the FCL samples group
well together, implying that these tumors share a
similar overall gene-expression pattern and arise
from germinal center cells.
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Fig. 12. A) Primary cutaneous Follicle center lymphoma (FCL): scanning magnification shows dense nodular lymphoid infiltrate. B) Primary
cutaneous FCL: the infiltrate consists of centrocyte-like and centroblast-like tumor cells. C) Primary cutaneous FCL: expression of CD20 by
tumor cells. D) Primary cutaneous FCL: the cells are bcl-2– (top) and bcl-6þ (bottom).
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Cutaneous diffuse large B-cell lymphoma (DLBCL)
Synonyms in other classifications
WHO/EORTC classification (2005): cutaneous dif-
fuse large B-cell lymphoma
WHO classification (2001): diffuse large B-cell
lymphoma
REAL classification (1997): diffuse large B-cell
lymphoma
EORTC classification (1997): primary cutaneous
large B-cell lymphoma of the leg
Primary cutaneous diffuse large B-cell lymphomas
(PCDLBCL) are composed of large B cells (centro-
blasts and immunoblasts).175,176 Two forms of pri-
mary cutaneous LBCL are distinguished in the
WHO-EORTC Consensus classification: DLBCL,
leg-type and DLBCL, other. The most common
variant, DLBCL, leg-type, usually occurs on the
leg and less frequently at other sites. Other variants
are referred to as DLBCL, other and comprise T-
cell/histiocyte-rich DLBCL, plasmablastic lym-
phoma and others that do not fulfill the criteria for
a DLBCL, leg-type. In former classifications, some
of these variants might have been referred to as
centroblastic lymphoma, immunoblastic lymphoma,
reticulohistiocytoma of the dorsum (Crosti disease),
anaplastic large-cell B-cell lymphomas, multilobate
large B-cell lymphomas, and still other names.
Diffuse large B-cell lymphoma (DLBCL), leg-type
Histology
A diffuse growth pattern is found with an mono-
morphous infiltrate involving the entire dermis.
Adnexal structures are usually destroyed (Fig. 13A).
The infiltrate may extend into subcutaneous tissue.
The epidermis is often spared with a Grenz zone.
The infiltrate is composed of monomorphic med-
ium-sized to large B cells resembling centroblasts
with large non-cleaved nuclei and nucleoli attached
to the nuclear membrane, or immunoblasts with a
large vesicular nucleus and a prominent centrally
placed nucleolus (Fig. 13B). In contrast to FCL,
centrocytes are absent. Mitotic figures can fre-
quently be detected. The nuclei are predominantly
round with coarsely clumped chromatin. There is
usually a minimal inflammatory component and
little stromal reaction.
BA
D
E
C
Fig. 13. A) Primary cutaneous diffuse large
B-cell lymphoma (DLBCL): dense, mono-
morphous lymphoid infiltrate through the
dermis; adnexa are destroyed. B) Primary
cutaneous DLBCL: infiltrate of large lym-
phoid cells with coarse chromatin and high
mitotic activity resembling mostly centro-
blasts. C) Primary cutaneous DLBCL: strong
CD79a positivity throughout the tumor; inset
shows high mitotic activity. D) Primary cuta-
neous DLBCL: strong bcl-2 positivity of
tumor cells. E) Primary cutaneous DLBCL:
Strong positivity of tumor cells for Mum-1.
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Immunophenotype
The tumor cells express CD19þ, CD20þ, CD22þ,
and CD79aþ (Fig. 13C), and CD5–, CD10–, and
CD138–, cyclin D1–. Bcl-6 is variably expressed
but mostly positive. Deletion or promoter region
hypermethylation of the p16INK4a gene was
detected in two patients with DLBCL. Loss of B-
cell markers also occurs.177 The strong positivity for
Bcl-2 protein (Fig. 13D) and MUM-1/IRF4178
(Fig. 13E) is an important feature of this type of
lymphoma, independent from the localization, leg
or other sites, distinguishing this entity from FCL
with diffuse growth pattern (Table 3). These immu-
nophenotypic features have been shown in nodal
DLBCL to correlate with an activated B-cell gene-
expression profile, which is usually predictive of an
aggressive clinical course.179 Among all primary
cutaneous large B-cell lymphomas, Bcl-6þ and
MUM-1 cases had a better overall survival than
Bcl-6–, MUM-1þ cases (176 vs. 26 months).180 In
the group of DLBCL leg type, MUM-1 is not a
prognostic marker.
Molecular findings and genetics
The immunoglobulin genes are clonally rearranged.
The t(14;18) can be detected in secondary cutaneous
large B-cell lymphomas but not in primary cuta-
neous diffuse large B-cell lymphomas. Expression
of p53 protein missense or loss-of-function muta-
tions in the p53 gene may be found in some patients
The bcl-2/JH translocation is absent.181–183
Significant differences have not been identified
among tumors of the leg-type arising in different
sites.178,182
In a study of gene expression profiles by Storz
et al.,174 analysis of arrays shows that primary cuta-
neous DLBCL cluster is adjacent to FCL samples,
whereas secondary cutaneous DLBCL cases are
removed from these two groups, suggesting that
they are biologically and molecularly distinct.
There is a characteristic B-cell germinal center
(GC) signature in tonsil, primary and secondary
cutaneous FCL, and in primary cutaneous
DLBCL, suggesting that these diseases are more
closely related than expected from earlier histologi-
cal and immunohistological analyses. In contrast,
secondary cutaneous DLBCL lacked the expression
of B-cell GC signature. Plasma cell signature on the
other side could be identified in two of five MZL
with prominent plasmacytoid differentiation.
Subsequently, Hoefnagel and colleagues184 studied
gene-expression profiles of eight primary cutaneous
FCL with a diffuse large-cell histology and 13
pcDLBCLs-leg using Affymetrix oligonucleotide
arrays. The pcDLBCL-leg lymphoma presented an
‘activated B cell’ ABC-like DLBCL expression pat-
tern, the primary cutaneous FCL a ‘germinal center
B’ GCB-like DLBCL transcription signature, as
defined by Wright et al.185 The transcript with the
greatest variation was SPINK2, whose function still
remains to be elucidated. It is highly expressed in
FCL, but absent or only very low in pcDLBCL leg
type samples. Consistent with previous studies,155
strong Bcl-2 protein expression was found in almost
all pcDLBCL leg type, but not in the FCL. In recent
years, staining for bcl-2, bcl-6, and CD10 has
become the standard marker set for differential diag-
nosis of cutaneous B-cell LPD as depicted in
Table 3. Additionally, MUM1/IRF4 seems to be of
value for delineating DLBCL with poorer outcome.
MUM1/IRF4 has been suspected to play a role in
the progression of B-cell lymphoma/leukemia by reg-
ulating the expression of various genes including the
monokine induced by interferon-gamma.186 In sys-
temic DLBCL, cases with coexpression of survivin
and T332 have a significantly worse prognosis than
single-positive and double-negative cases, and so sur-
vivin and the novel monoclonal antibody, T332,
might be of prognostic value for this group. High
levels of caspase 3 and absence of p16 expression in
pcDLBCL also indicate a poor prognosis.187
The pathologic, immunophenotypic and molecu-
lar features of primary cutaneous large B-cell lym-
phoma of the leg and at other sites indicate that they
are similar both with morphofunctional and mole-
cular profiles, and therefore it is justified to refer to
altogether as DLBCL, leg-type in analogy to similar
terms in the classification of lymphomas such as
nasal type.
Diffuse large B-cell lymphoma, other
This term refers to other lymphomas showing a
diffuse growth pattern, composed of large trans-
formed B-cells that lack the typical features of
DLBCL, leg-type and do not conform to the defini-
tion of primary cutaneous FCL with diffuse growth
pattern. These tumors contain a monomorphic
population of centroblast-like cells and often present
Table 3. Summary on phenotypical features of cutaneous B-cell lym-
phomas and pseudolymphomas
Bcl-2 Bcl-6 CD10 (14; 18) MUM1/IRF4
MZL/ICY þ – – – –
FCL – þ þ/– – –
Secondary FCL þ þ þ þ –
DLBCCL þ þ – –/þ þ
PSL – þ þ – –
MZL/ICY, marginal zone lymphoma/immunocytoma; FCL, follicle center
lymphoma; Secondary FCL secondary cutaneous FCL; DLBCL, diffuse
large B-cell lymphoma; PSL, pseudolymphoma or reactive lymphoid
hyperplasia. The term pseudolymphoma is used by dermatologists as a
synonym for any type of reactive infiltrate in the skin that is extensive
enough to cause a tumor or nodule.
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with a mixed inflammatory background. Bcl-2 pro-
tein may be negative, whereas bcl-6 will usually be
expressed.
T-cell/histiocyte-rich diffuse large B-cell lymphoma
This rare variant of a DLBCL is defined by the
predominance of non-neoplastic T cells admixed
with scattered large tumoral B cells.188
Histology
There are a few large pleomorphic cells with clear
cytoplasm and multilobular nuclei resembling
Hodgkin or Reed–Sternberg cells scattered within
a background of reactive small T lymphocytes
(>75%) (Fig. 14), some of which have irregular
nuclear contours, epithelioid histiocytes, and plasma
cells. Centroblasts and immunoblasts can be
observed. There may be a marked vascular prolif-
eration in some cases.188,189
Immunophenotype
The large neoplastic cells express pan-B-cell anti-
gens CD19 (Fig. 14), CD22, and CD79a, with
light-chain restriction, but are negative for CD15
and CD30, which excludes Hodgkin lymphoma.
The reactive small-cell population represents T-
helper cells but small reactive B cells can also be
found.190 Due to the lower number of tumor cells,
detection of IgH gene rearrangements may be diffi-
cult to assess in some cases.
Intravascular large B-cell lymphoma (IVL)
Synonyms in other classifications
WHO/EORTC classification (2005): intravascular
large B-cell lymphoma
WHO classification (2001): intravascular large B-cell
lymphoma (IV-LBL)
REAL classification (1997): diffuse large B-cell
lymphoma
EORTC classification (1997): intravascular large
B-cell lymphoma (provisional entity)
Intravascular lymphoma is a rare highly malig-
nant large-cell lymphoma with systemic spread,
characterized by the presence of tumor cells in the
lumina of small vessels, particularly capillaries and
venules. The skin and the nervous system are pre-
ferential sites of primary manifestation. The tumor
cells express B-cell markers in the vast majority of
cases; rarely a T-cell phenotype is found. Other
synonyms include systemic angioendotheliomato-
sis,191 intravascular lymphomatosis, and
Tappeiner–Pfleger syndrome. Neoplastic angioen-
dotheliomatosis has to be differentiated from reac-
tive angioendotheliomatosis, which may develop in
conjunction with a variety of underlying systemic
inflammatory or neoplastic diseases.192,193 Patients
with disease limited to the skin (cutaneous variant)
have a significantly better outcome than the other
patients with IVL.194
Histology
The microscopic features are pathognomonic show-
ing a dense proliferation of atypical large lymphoid
cells with round or oval nuclei within the lumina of
capillaries and postcapillary venules195,196 (Fig. 15).
Tumor cells are large with vesicular nuclei, promi-
nent nucleoli, and frequent mitoses. Partial occlu-
sion of vessels by tumor cells and fibrin thrombi
results in the clinical features of reticular erythema
and livedo reticularis. Extravascular involvement
may occur.197
Fig. 14. T cell-rich B-cell lymphoma (BCL): detail of the infiltrate
consisting of many reactive T lymphocytes (smaller cells) and scat-
tered large blastic B cells. Inset: large cells are positive for CD20.
Fig. 15. Intravascular large B-cell lymphoma: large atypical blastic
B cells intravascularly.
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Immunophenotype
Tumor cells usually express B-cell-associated anti-
gens and may coexpress CD10 or CD5,198,199
CD11a, and CD49d (VLA-4).200 Most IVLs over-
express bcl-2 protein.197 Rare cases with a T-cell
phenotype have been described. There is no bcl-2
gene rearrangement.25,201,202 These cases have to be
distinguished from other intravascular lymphomas
of different lineages.203–205 A defect in homing
receptors and adhesion molecules on the neoplastic
cells and the endothelial cells has been suggested to
be responsible for the intravascular trapping of lym-
phoid tumor cells.206,207 However, the precise
mechanisms of lymphoid–endothelial interaction
leading to vascular occlusion and thrombotic events
are not clear.
Molecular findings and genetics
Rearrangements of IgH family genes is seen in IVL.
Structural aberrations in chromosomes 1, 6, and 18,
especially 1p and trisomy 18, have been found in
some cases.208 Mutations of p53, p16, and p21
genes do not seem to be involved with IVL cells.209
CD29 (beta1 integrin subunit), CD43 (leukosialin),
CD44 (H-CAM), CD54 (ICAM-1), embryonal N-
CAM (e-NCAM), and episialin are molecules
known to be involved in lymphocyte and endothelial
adhesion processes.207 In IVL, the intravascular neo-
plastic lymphocytes express CD44 but are negative
for CD29 and for CD54. The absence of CD29 and
CD54 in IVL may contribute to the intravascular
and disseminated distribution pattern.207
Blastic NK-cell lymphoma or CD4þ/CD56þ hematodermic
neoplasm
Synonyms in other classifications
WHO/EORTC classification (2005): CD4þ/
CD56þ hematodermic neoplasm; blastic NK-cell
lymphoma
WHO classification (2001): blastic NK-cell lymphoma
REAL classification (1997): not listed
EORTC classification (1997): not listed
Although the cell of origin is not yet completely
elucidated, the immunophenotypic profile (CD4þ,
CD56þ, and CD123þ) suggests that the tumor
cells represent most probably precursor cells related
to activated plasmacytoid monocytes.210
Cytogenetically, they are related to myeloid and to
lymphoid precursor cells (type 2 dendritic cells).
Skin involvement occurs in 87% of the patients
and manifests with contusiform, brownish infiltrated
plaques or nodules.211,212 The oral mucosa is com-
monly involved.
Histology
Histologically, monomorphous, non-epidermotropic
medium-to-large-sized tumor cells with round or
pleomorphic nuclei form a diffuse dense infiltrate
throughout the dermis, separated from the epider-
mis by a small Grenz zone (Fig. 16). Erythrocyte
extravasation is a characteristic feature, explaining
the bruise-like appearance.
Immunophenotype
The cells express CD4, CD56, CD123 and TCL-1
but are negative for other T-, B-, NK-cell, or mye-
loid markers. In contrast myelomonocytic neo-
plasms coexpresses CD43 and CD74 in addition to
myeloid markers (CD13, CD15, myeloperoxidase,
and lysozyme). A minority of tumor cells in some
cases also may express CD68 or TdT.213
Molecular findings and genetics
Because the tumor cells are not related to T-cells,
there is no clonal rearrangement of TCR genes.
Fig. 16. Blastic natural killer-cell lymphoma: dense diffuse infiltrate
throughout the dermis, sparing the grenz zone; left inset: large
blastic cells with coarse chromatin, nucleoli and high mitotic activ-
ity; right inset: CD56þ tumor cells.
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Conclusions
Because the microscopic studies of Xavier Gillot
(1842–1910) and Louis Antoine Ranvier (1835–
1922) in Paris indicated that MF was caused by
regeneration of lymphoid tissue in the skin and
that MF had to be considered as a cutaneous man-
ifestation of lymphoma–lymphade´nie cutane´e,214
there has never been a reason for classifying cuta-
neous lymphomas differently from lymphomas at
other sites with same pathogenetic background.
The new WHO/EORTC classification of cuta-
neous lymphomas, which employs a terminology
compatible with systemic lymphomas but also
reflects the organ-specific pecularities of cutaneous
lymphomas.
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